Literature DB >> 12685448

[Alteration of the guidelines on pharmaceuticals of the National Committee of Physicians and Health Insurers with regard to atypical neuroleptics. Statement of the German Scoiety of Psychiatry, Psychotherapy and Neurology (DGPPN)].

J Fritze, M Schmauss.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12685448

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  2 in total

1.  [Cost predictors of depressive inpatient episodes in Germany. The health insurer's point of view].

Authors:  K Stamm; H J Salize; M Härter; S Brand; P Sitta; M Berger; W Gaebel; F Schneider
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

2.  [Differential indications for atypical neuroleptics: Amisulprid, Clozapin, Olanzapin, Quetiapin und Risperidon. Results of a pilot study of prescription habits in psychiatric clinical usage in the BRD].

Authors:  W Günther; G Laux; W Trapp; N Müller; N Mitznegg; H Schulze-Mönking; R Steinberg; M Wolfersdorf
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.